Overview
Valued at
~$131.5 million in 2023, the tricuspid valve repair devices market is projected to
reach
~$275.5 million by 2028, increasing at a
CAGR of 15.9% over the
2023-2028 forecast period. This Market Snapshot is part of
LSI’s Market Intelligence platform, your
one-stop-shop for global medtech market sizing and analysis, procedure volume data, startup company- and
deal-tracking, curated insights, and more.
Tricuspid valve repair is the preferred surgical approach for treating degenerative tricuspid valve disease,
typically performed in conjunction with annuloplasty to reshape the tricuspid valve’s annulus. The market for
tricuspid valve repair devices is currently experiencing a renaissance, driven by the introduction and
development of transcatheter solutions for tricuspid valve repair and replacement. As of the publication of this
snapshot, transcatheter devices for both tricuspid valve repair and replacement have been approved. Similar to
the aortic and mitral valves, a transcatheter approach for the tricuspid valve will expand treatment options to
patients previously ineligible for surgery due to high procedural risks.
Products included within the scope of this analysis include:
Tricuspid valve annuloplasty rings
Transcatheter tricuspid valve repair devices
This Market Snapshot is intended to provide a high-level overview of the global market for tricuspid valve
repair devices, with key insights into:
Unit volumes from 2023 to 2028
Market forecasts from 2023 to 2028
Market insights
Competitive landscape analysis of major competitors
Insights into key market events for strategic and startups
Tricuspid Valve Repair Devices Market Snapshot Summary
| Snapshot Aspect |
Data and Details |
| Base Year for Estimate |
2023 |
| Forecast Period |
2023 - 2028 |
| Market Size in 2023 |
$131.5 million |
| CAGR |
15.9% |
| Projected Market Size in 2028 |
$275.5 million |
Tricuspid Valve Repair Devices Market Insights
The tricuspid valve repair devices market is experiencing robust growth, largely driven by the introduction of
new transcatheter devices that offer minimally invasive options for patients previously ineligible for surgery
due to high operative risks. Historically, tricuspid valve repair was limited to annuloplasty rings implanted
through open surgery, with devices such as the Carpentier-Edwards Physio Tricuspid annuloplasty ring. However,
recent advancements in percutaneous devices are transforming the market.
Abbott’s TriClip system, which received a CE mark in 2020, was the first to offer a minimally invasive solution
for tricuspid valve repair. Edwards’ EVOQUE system, approved by the FDA in 2024, is the first device to offer a
minimally invasive option for complete tricuspid valve replacement without the need for open-heart surgery.
These new devices—which command premium prices—are expected to drive significant growth in the market by
reducing procedural risks and expanding treatment options. However, the market remains in its early stages, and
continued adoption will depend on the ongoing development and clinical acceptance of these technologies.
Competitive Landscape
The full Market Snapshot includes a robust analysis of the competitive landscape for the tricuspid valve repair
devices market. This includes estimated market revenue and market share for key players, such as Edwards
Lifesciences, Medtronic, and Abbott.
Select Market Events
|
Company
|
Date
|
Type
|
Event
|
|
|
2/2024
|
Regulatory Approval
|
Edwards Lifesciences received U.S. FDA Approval for its EVOQUE tricuspid valve replacement
system for treating tricuspid regurgitation.
|
|
|
4/2024
|
Regulatory Approval
|
Abbott announced that its TriClip G4 transcatheter edge-to-edge repair system for treating
tricuspid regurgitation has received regulatory approval from the U.S. FDA.
|
Key Companies Covered
Abbott
Edwards Lifesciences
Laplace Interventional
Medtronic
Mitral Holdco
OrbusNeich
StarTric
Tioga Medical
